Amicus Therapeutics, Inc. (NASDAQ:FOLD)
| CAPS Rating |
|
|---|---|
| Open | $6.67 |
| Previous Close | $6.78 |
| Daily Range | $6.51 - $6.71 |
| 52-Week Range | $2.10 - $8.12 |
| Market Cap | $231.82M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 86,598 |
| Average Daily Volume | 0 |
FOLD
VS S&P 500 (SPY)
How do you think FOLD will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
FOLD Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
FOLD News and Commentary
- 22 Companies With Market Cap Over $50 Million and 100%-Plus Sales Growth Forecast for 2011-12 – SeekingAlpha
- Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Amicus Therapeutics CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha
- Biotech Ends October With Almost $1B in IPOs, $3B in M&A Activity, $3B in Possible Partnerships – SeekingAlpha
- Amicus Agreement with GSK - Call Transcript – SeekingAlpha Transcripts
- Amicus Agreement with GSK - Call Transcript – SeekingAlpha
- Amicus Therapeutics Agreement with GSK - Call Transcript – SeekingAlpha Transcripts
- 2nd UPDATE: Glaxo Licenses Fabry Disease Drug From Amicus – SmartMoney
- GlaxoSmithKline And Amicus Therapeutics Enter Amigal Pact – SmartMoney
- Pfizer Takes an Orphan Into the Fold – The Motley Fool
- FDA, Clinical Trial Binary Events: Amarin, Amicus, Labopharm – SeekingAlpha
- Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript – SeekingAlpha Transcripts
- Amicus Therapeutics, Inc. Q2 2010 Earnings Call Transcript – SeekingAlpha
- Data for Bottom Fishers - June 29, 2010 – Blog at The Motley Fool
- Three more bottoms that might be good in a pinch – Blog at The Motley Fool
- UPDATE 1-Amicus Q3 loss narrower than view; ends Shire pact – Reuters
- Monday's Biggest Stock Stars – The Motley Fool
- UPDATE 1-Amicus' Gaucher drug fails in mid-stage trial – Reuters
- Genzyme Playing Defense – The Motley Fool
- Late to the Party – The Motley Fool
RSS Headlines
Fool UK
